is the tirzepatide shortage over FDA Says of GLP-1 FDA confirms end of Eli

Patients have reported side effects like nausea and digestive discomfort, especially when starting the medication or increasing the dosage

But roughly 10% to 15% of patients in those trials were nonresponders who lost less than 5% of their body weight

doi: 10.1021/jacs.0c06590 96

Active eating disorder If you are managing binge eating disorder or another eating disorder that tirzepatide has helped control, stopping the medication requires coordination with a mental health professional who specializes in eating disorders

However, these are separate trials with different populations and cannot be directly compared with the same certainty as a head-to-head study